logo-loader

Full interview: Humanigen exploring potential therapeutic for lung damage arising from Coronavirus

Published: 11:43 10 Mar 2020 EDT

Humanigen (OTCQB: HGEN) CEO Cameron Durrant joined Steve Darling from Proactive in Vancouver to discuss the company that it is actively exploring clinical-stage strategies and partnerships to evaluate whether "lenzilumab", the company’s proprietary monoclonal antibody, may reduce or prevent cytokine storm resulting from COVID-19 infection. 

Durrant talked about cytokine storms and their relation to a virus like Corona.   

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

7 hours, 23 minutes ago